←
Jenny Seligmann971 posts
Jenny Seligmann avatar

Jenny Seligmann

@JenSeligmann

Optimist. Prof GI medical oncology. Coffee, Irn-Bru & dog enthusiast @foxtrotstudy @focus4trial @ArielTrial #pelotonuk 🇪🇺

◷ Joined October 2014▧ 99 Photos and videos
Annals of Oncology avatar
⟳ Jenny Seligmann retweeted
Annals of Oncology@Annals_Oncology·8 May 2025

🆕Article of the Month podcast🎧: @tompowles1 discusses the FOxTROT trial in locally advanced colon cancer with @JenSeligmann tinyurl.com/2sv3eyf4 For the full study report see: doi.org/10.1016/j.annonc.202…

Jenny Seligmann avatar
Jenny Seligmann@JenSeligmann·23 Oct 2025

Neoadjuvant IO for locally advanced MSS colon ca…. This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection. 💥💥huge congrats to my team neoadjuvant dear friend and team! We will get there in colon cancer

Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.

Post attachment
Jenny Seligmann avatar
Jenny Seligmann@JenSeligmann·21 Oct 2025

Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC -Neoadjuvant IO superior to chemo -20% relapses with chemo in "good prognosis" group; 30% if T4 -Minimal path response to chemo - Clinical staging identified high risk group

Post attachmentPost attachmentPost attachment
Jenny Seligmann avatar
Jenny Seligmann@JenSeligmann·21 Oct 2025

Thanks for highlighting!! @MyriamChalabi

NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67% pathologic CR • Zero recurrences to date at 3 years 🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago. The real question now: with Cercek’s rectal data, can we safely omit surgery next? At minimum, this should be the new standard. At maximum, it’s the start of a paradigm shift. @OncoAlert @TheGutOncLab #ESMO25

Post attachmentPost attachmentPost attachment
ESMO Open avatar
⟳ Jenny Seligmann retweeted
ESMO Open@ESMO_Open·25 Jul 2025

Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. esmoopen.com/article/S2059-7…

Post attachment
Jenny Seligmann avatar
Jenny Seligmann@JenSeligmann·13 Jan 2025

🤔Pani had little effect on path response 👍Prospective trial in LACC RAS/RAF-wt EREG/AREG pts planned ❓Consider in LARC This will be my last tweet - hope to see you on Bluesky 👋 @b

Jenny Seligmann avatar
Jenny Seligmann@JenSeligmann·13 Jan 2025

🎆 Now online - my 2 fav topics in one paper 👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer 👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts ❓Time to re-think targeted agents in LACC/LARC annalsofoncology.org/article…

Angela Lamarca avatar
⟳ Jenny Seligmann retweeted
Angela Lamarca@DrAngelaLamarca·7 Dec 2024

Just finished. Very interesting #MiniOral #ESMOAsia24 session in #PDAC and #Biliary that I had the pleasure to co-chair (and discuss) with @JenSeligmann Posts coming with my thoughts 😉 Thanks @LorenzaRimassa for the 📸 🫶 @myESMO

Post attachment

The mini oral session on #GI cancer continues at #ESMOAsia24 in #Singapore. More abstracts on gastric, gastroesophageal, and GEJ cancer, but also on #BTC and #PDAC @myESMO @DrAngelaLamarca @JenSeligmann

Post attachmentPost attachmentPost attachmentPost attachment